Monopar Therapeutics Inc (MNPR)

In the past six months, Monopar Therapeutics' stock price has been impacted by several events. The company reported an EPS of -$0.48 in the Q3 2025 earnings report, missing analysts' consensus estimates of -$0.46. Monopar Therapeutics announced the pricing of a $135 million underwritten offering of common stock and pre-funded warrants. The company was included in the Russell 3000® and Russell 2000® Indexes. Shares of Monopar Therapeutics underwent a 1-5 reverse stock split. Monopar Therapeutics' stock has shown a significant increase over the past year, with a 147.57% rise between January 10, 2025, and January 9, 2026, and as of January 9, 2026, the share price was $62.76. Monopar Therapeutics' CFO, Quan Anh Vu, bought 1,500 shares of the company's stock on December 26, 2025.

As a clinical-stage biopharmaceutical company, Monopar Therapeutics, Inc. does not currently have commercialized products generating sales revenue. Therefore, the concept of demand seasonality for its products and services is not applicable at this stage of its development. The company's value is primarily derived from its intellectual property and the clinical progress of its pipeline assets.

Monopar Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with significant unmet medical needs, primarily in oncology and rare diseases. The company operates within the biotechnology and pharmaceutical industry, specializing in the development of novel radiopharmaceuticals for oncology and a new treatment for Wilson Disease. The company builds its drug development pipeline through both in-house efforts and the licensing of late preclinical and clinical-stage therapeutics. Its major product candidates include ALXN1840 (bis-choline tetrathiomolybdate), a late-stage, investigational, once-daily, oral medicine for Wilson Disease, and the MNPR-101 Series, a proprietary humanized monoclonal antibody platform for advanced cancers, targeting the urokinase plasminogen activator receptor (uPAR) expressed on solid tumors. The MNPR-101 series includes MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent conjugated to zirconium-89, MNPR-101-Lu, a clinical-stage radiotherapeutic conjugated to lutetium-177, and MNPR-101-Ac, a late-preclinical stage radiotherapeutic conjugated to actinium-225.

Monopar Therapeutics, Inc. is headquartered in Wilmette, Illinois, United States. The company focuses on developing therapeutics for the treatment of cancer in the United States. Monopar also has international subsidiaries, specifically Monopar Therapeutics Pty Ltd and Monopar Therapeutics SARL.

In the past year, Monopar Therapeutics has maintained a generally positive brand reputation, primarily driven by its scientific advancements and analyst confidence. The company has received a consensus "Buy" rating from analysts, with an average rating score of 3.00 based on multiple strong buy and buy ratings. Monopar presented new data and analyses on ALXN1840 for Wilson Disease at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2025 in November 2025, and had an abstract accepted for oral presentation at the American Neurological Association Annual Meeting in September 2025. A physicians' letter to the editor demonstrating ALXN1840 rapidly improved copper balance in Wilson Disease patients was published in the Journal of Hepatology in September 2025. The purchase of company stock by the CFO in December 2025 can be seen as a positive signal of insider confidence. While generally positive, a comparison of media sentiment with a competitor, Dianthus Therapeutics, indicated that Monopar Therapeutics had a lower average media sentiment score.

Monopar Therapeutics, Inc. has a diverse ownership structure, with significant institutional and insider holdings. Institutional shareholders hold 64.89% of the stock, while Monopar Therapeutics insiders hold 287.67%. Major institutional owners include Janus Henderson Group Plc, Adage Capital Partners Gp, L.L.C., Ra Capital Management, L.P., Wellington Management Group Llp, Vanguard Group Inc, BlackRock, Inc., Deerfield Management Company, L.P. (series C), Saturn V Capital Management LLC, TCG Crossover Management, LLC, and ADAR1 Capital Management, LLC. Key individual insider owners include Arthur J. Klausner, who is the largest individual shareholder, owning 9.17 million shares representing 137.30% of the company, and Michael J. Brown, owning 4.80 million shares representing 71.91% of the company.